Version 3 2024-06-19, 06:45Version 3 2024-06-19, 06:45
Version 2 2024-06-05, 11:07Version 2 2024-06-05, 11:07
Version 1 2021-11-22, 10:39Version 1 2021-11-22, 10:39
journal contribution
posted on 2024-06-19, 06:45authored byJS Ong, Suzanne Dixon-SuenSuzanne Dixon-Suen, X Han, J An, R Fitzgerald, M Buas, MD Gammon, DA Corley, NJ Shaheen, LJ Hardie, NC Bird, BJ Reid, WH Chow, HA Risch, W Ye, G Liu, Y Romero, L Bernstein, AH Wu, DE Whiteman, T Vaughan, M Agee, B Alipanahi, A Auton, RK Bell, K Bryc, SL Elson, P Fontanillas, NA Furlotte, DA Hinds, KE Huber, A Kleinman, NK Litterman, MH McIntyre, JL Mountain, ES Noblin, CAM Northover, SJ Pitts, JF Sathirapongsasuti, OV Sazonova, JF Shelton, S Shringarpure, C Tian, JY Tung, V Vacic, CH Wilson, U Liyanage, JC Dusingize, J Schumacher, I Gockel, A Böhmer, J Jankowski, C Palles, T O’Mara, A Spurdle, MH Law, MM Iles, P Pharoah, A Berchuck, W Zheng, AP Thrift, C Olsen, RE Neale, P Gharahkhani, PM Webb, S MacGregor
AbstractPrevious Mendelian randomization (MR) studies on 25-hydroxyvitamin D (25(OH)D) and cancer have typically adopted a handful of variants and found no relationship between 25(OH)D and cancer; however, issues of horizontal pleiotropy cannot be reliably addressed. Using a larger set of variants associated with 25(OH)D (74 SNPs, up from 6 previously), we perform a unified MR analysis to re-evaluate the relationship between 25(OH)D and ten cancers. Our findings are broadly consistent with previous MR studies indicating no relationship, apart from ovarian cancers (OR 0.89; 95% C.I: 0.82 to 0.96 per 1 SD change in 25(OH)D concentration) and basal cell carcinoma (OR 1.16; 95% C.I.: 1.04 to 1.28). However, after adjustment for pigmentation related variables in a multivariable MR framework, the BCC findings were attenuated. Here we report that lower 25(OH)D is unlikely to be a causal risk factor for most cancers, with our study providing more precise confidence intervals than previously possible.